SEARCH:   Advanced

Blood, 15 January 2008, Vol. 111, No. 2, pp. 544-548. Prepublished online as a Blood First Edition Paper on October 1, 2007; DOI 10.1182/blood-2007-07-100719. This Article Full Text (PDF) All Versions of this Article: blood-2007-07-100719v1 111/2/544    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Quinn, C. T Articles by Buchanan, G. R Search for Related Content PubMed PubMed Citation Articles by Quinn, C. T Articles by Buchanan, G. R Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 19, 2007 Accepted September 25, 2007 Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort Charles T Quinn*, Nancy J Lee, Elizabeth P Shull, Naveed Ahmad, Zora R Rogers, and George R Buchanan Department of Pediatrics, Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States Southwestern Comprehensive Sickle Cell Center, Dallas, TX, United States Children's Medical Center Dallas, Dallas, TX, United States * Corresponding author; email: charles.quinn{at}utsouthwestern.edu. The Cooperative Study of Sickle Cell Disease (CSSCD) reported that dactylitis, severe anemia, and leukocytosis in very young children with SCD increased the risk of later adverse outcomes, including death, stroke, frequent pain, and recurrent acute chest syndrome (ACS). This model has not been validated in other cohorts. We evaluated its performance in the Dallas Newborn Cohort (DNC), a newborn inception cohort of children with sickle cell disease. We studied 168 children (55% male, 97% SS) with a mean follow-up of 7.1 years who provided 1,188 patient-years of observation. Twenty-three (13.7%) subjects experienced adverse events: 2 (1.2%) died, 14 (8.3%) had a stroke, 4 (2.4%) had frequent pain, and 3 (1.8%) had recurrent ACS. There was no relationship between the early clinical predictors and later adverse outcomes, with the possible exception of leukocyte count. Most subjects who experienced adverse events were predicted to be at low risk for adverse events. No subject who was predicted to be at high risk actually experienced an adverse outcome. The sensitivity of the model did not rise above 20% until specificity fell below 60%. We suggest that this model should not be used as a criterion to initiate early interventions for sickle cell disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Sickle severity selectors strike out Ellis J. Neufeld Blood 2008 111: 479. [Full Text] [PDF] This article has been cited by other articles: J. D. Beckman, J. D. Belcher, J. V. Vineyard, C. Chen, J. Nguyen, M. O. Nwaneri, M. G. O'Sullivan, E. Gulbahce, R. P. Hebbel, and G. M. Vercellotti Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1243 - H1253. [Abstract] [Full Text] [PDF] N. Patel, C. S. Gonsalves, M. Yang, P. Malik, and V. K. Kalra Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease Blood, January 29, 2009; 113(5): 1129 - 1138. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020